CABERGOLINE

Written By:P. Thirumal ReddyB. Pharm Reviewed By:Dr. Tejashwin AdigaMBBS

Last updated on 31 Mar 2026 | 09:29 AM (IST)

CABERGOLINE

Background and Date of approval CABERGOLINE

Cabergoline was first developed in the early 1990s as a long-acting dopamine agonist to address prolactin-related disorders. It quickly gained prominence due to its extended half-life and efficacy in controlling prolactin levels. Cabergoline is classified as an ergot derivative and differs from older agents like bromocriptine due to its improved tolerability and patient compliance.
Cabergoline was approved by the U.S. Food and Drug Administration (FDA) on December 23, 1996, for the treatment of hyperprolactinemia. Since then, it has been widely used in clinical practice for various indications related to prolactin excess and dopamine receptor-related conditions.

Uses of CABERGOLINE

Cabergoline is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. It is also used in the management of Parkinson's disease and for the inhibition of lactation.

How is CABERGOLINE administered?

Cabergoline is administered orally, preferably with food to reduce gastrointestinal side effects. The dosage varies based on the condition being treated:

Hyperprolactinemia: The typical starting dose is 0.25 mg twice a week, which may be increased by 0.25 mg twice weekly increments, depending on the patient's serum prolactin levels, up to a maximum of 1 mg twice a week.
Parkinson's Disease: Doses and schedules vary; consult a healthcare provider for individualized dosing.

Side Effects of CABERGOLINE

Common side effects include:

Nausea
Headache
Dizziness
Fatigue
Constipation

Serious side effects may include cardiac valvulopathy, pulmonary fibrosis, and psychiatric symptoms such as hallucinations.

Warnings

Cardiac Valvulopathy: Cabergoline has been associated with heart valve problems. Regular monitoring through echocardiograms is recommended.
Fibrotic Complications: There is a risk of fibrotic reactions affecting the lungs, heart, and abdomen.
Hypotension: Cabergoline can cause orthostatic hypotension; caution is advised, especially during dose escalation.

Precautions

Psychiatric Disorders: Use with caution in patients with a history of serious mental illness, particularly psychotic disorders.
Hepatic Impairment: Dose adjustment may be necessary in patients with liver dysfunction.
Pregnancy and Lactation: Cabergoline is contraindicated during lactation and should be used in pregnancy only if clearly needed.

Word of Advice

Before starting cabergoline, inform your healthcare provider about any existing medical conditions, especially cardiovascular diseases, lung diseases, or psychiatric disorders. Regular monitoring of cardiac function and prolactin levels is essential during treatment. Avoid activities requiring mental alertness, such as driving or operating machinery, until you know how cabergoline affects you, as it may cause dizziness or sudden sleep onset.

Frequently Asked Questions

Q1.

What is Cabergoline used for?

Cabergoline is primarily used to treat hyperprolactinemia, a condition where there are high levels of prolactin in the blood. It is also prescribed for prolactin-secreting pituitary tumors (prolactinomas), menstrual irregularities, and infertility caused by elevated prolactin. Additionally, it is used to suppress lactation in specific medical situations, such as after an abortion or stillbirth.

Q2.

How does Cabergoline work?

Cabergoline works by acting on the dopamine receptors in the brain, specifically in the pituitary gland, where it inhibits the secretion of prolactin. By reducing prolactin levels, it helps restore normal menstrual cycles, reduces milk production (in cases of lactation suppression), and improves fertility in women affected by high prolactin levels.

Q3.

Can Cabergoline be taken during pregnancy?

Cabergoline should be used during pregnancy only if clearly needed. It is categorized as a Category B drug by the FDA, which means animal studies have not shown a risk to the fetus, but there is insufficient data on its safety in pregnant women. Discuss with your doctor if you are pregnant or planning to become pregnant before taking Cabergoline.

Q4.

Can Cabergoline affect my heart?

Yes, Cabergoline can cause cardiovascular side effects, including valvular heart disease or fibrosis (scar tissue formation) in rare cases. It is recommended to have regular heart checks, such as echocardiograms, especially for those taking the medication long-term or those with pre-existing heart conditions.

References

Disclaimer

This information is provided for educational purposes and should not replace professional medical advice. Consult a healthcare professional for personalized recommendations.

;